Medical news today: Wednesday, October 28, 2026
Lancet Countdown calls climate a health emergency, UK drug shortages bite, and India's top court slams its drug regulator
Get tomorrow's issue in your inbox.
- 01
STAT investigation finds Epic withholds patient data access from rivals (STAT+, paywall)
Source: STAT
STAT reports: A STAT investigation found that Epic selectively withholds access to patient data, disadvantaging rival software developers and stymying innovation.
Why it mattersSTAT found that Epic selectively withholds access to patient data, which disadvantages rival software developers and slows innovation in health technology.
- 02
Eli Lilly climbs diabetes reputation rankings, closing in on Novo
Source: Fierce Pharma
Why it mattersFierce Pharma reports Lilly has moved up the diabetes reputation rankings and is now close to Novo, a sign of how the two leading diabetes drugmakers compare in standing. More on Obesity & metabolic →
- 03
Cochrane review finds workplace ergonomics do little for arm, neck and shoulder pain
Source: Medical Xpress
An updated Cochrane review (a large summary of earlier studies) found ergonomic changes at work showed no meaningful benefit for pain, function, recovery or sick leave in workers with work-related arm, neck or shoulder complaints, compared with no treatment.
Why it mattersOffice workers and employers spend money on desks, chairs and setups hoping to prevent pain; this review suggests those changes alone may not help much, so people with ongoing pain may need other options discussed with a clinician.
- 04
UK patients go without MS pain drug nabilone as shortage hits wholesalers
Source: BBC Health
A woman with multiple sclerosis (MS) told the BBC she has spent most of her time in bed since running out of nabilone, a cannabis-like medicine she has used for pain for 17 years. Northern Ireland's health department said the drug is out of stock with UK wholesalers and not expected back until December; an industry tracker (MIMS) counts 157 drugs in short supply in the UK this week, up from 107 in January.
Why it mattersMedicine shortages are rising in the UK, and patients who rely on one specific drug can be left without it for weeks, so it is worth asking a pharmacist early about alternatives if a regular prescription becomes hard to fill. More on Infectious disease →
Market news · Not investment advice
- 05
Lancet Countdown says climate change is now a global health emergency
Source: The Lancet
The 10th annual Lancet Countdown report, by 146 researchers with WHO, estimates heat was linked to about 540,800 deaths a year in 2016-2023, 68% of them caused by climate change, and a record 710,000 deaths in 2023. It says heat cost the world an estimated $1.07 trillion in lost work income in 2025, with Southeast Asia and Africa hit hardest, and calls for climate change to be treated as a global health emergency.
Why it mattersHotter years mean more heat deaths and lost wages, especially for outdoor workers in farming and construction in poorer regions, which is why the authors want health to drive climate policy and funding. More on Drug & device safety →
- 06
Early trial finds new alpha radiation drug well tolerated in advanced prostate cancer
Source: Medical Xpress
A new alpha-emitting radiopharmaceutical (a drug that carries a tiny radioactive payload straight to cancer cells) for advanced prostate cancer caused no dose-limiting side effects and showed encouraging early signs of anti-tumour activity, according to an early-phase trial in The Journal of Nuclear Medicine.
Why it mattersRadiation drugs that target tumours are a growing option for men with prostate cancer that has spread; this is an early, small-stage result, so larger trials are needed before it could reach patients. More on Oncology →
- 07
US Congress weighs fixes to the surprise billing law
Source: MedPage Today
MedPage Today reports that while most observers agree the US No Surprises Act stopped unexpected bills for out-of-network care, lawmakers are still trying to fix other problems the law created.
Why it mattersThe law shields US patients from surprise medical bills, so any changes Congress makes could affect what patients, insurers and doctors pay after emergency or out-of-network care.
- 08
Phase 3 data suggest fenebrutinib may curb smouldering MS lesions
Source: MedPage Today
Data from phase 3 trials presented at the ECTRIMS multiple sclerosis meeting suggest the experimental pill fenebrutinib, a BTK inhibitor (a drug that calms certain immune cells), may curb chronic active lesions, areas of brain damage that slowly keep growing in MS.
Why it mattersSlowly expanding lesions are linked to MS getting worse over time even when relapses are controlled, so a pill that may target them could matter to people living with MS; it is still investigational. More on Neurology →
- 09
Lyme vaccine candidate tops 70% efficacy but narrowly misses trial goal
Source: MedPage Today
An investigational Lyme disease vaccine covering six serotypes across four Borrelia species had a vaccine efficacy of over 70% in a placebo-controlled late-stage trial, but just missed a preset threshold, MedPage Today reports from the IDWeek meeting in Washington.
Why it mattersThe vaccine protected more than 70% of the time yet missed its preset goal, so the result leaves its path forward uncertain for people at risk of Lyme disease. More on Infectious disease →
- 10
Ferring agrees to buy IVF startup Gameto for up to $1.4 billion
Source: BioPharma Dive
Fertility drugmaker Ferring will acquire Gameto for up to $1.4 billion, BioPharma Dive reports, gaining rights to technology designed to simplify the long and burdensome in vitro fertilisation (IVF) process.
Why it mattersIVF is costly and demanding for patients; big investment in simpler methods could eventually change what treatment involves and costs. Not investment advice. More on Markets →
Market news · Not investment advice
- 11
AI tool may help find rare sperm in men told they have none
Source: MedPage Today
An AI-powered tool called STAR (Sperm Tracking and Recovery) could be a last resort for couples who want a biological child after the man was told he has no sperm (azoospermia), researchers said at the ASRM fertility meeting in Baltimore, MedPage Today reports.
Why it mattersMen with azoospermia often have few options for fathering a biological child; if confirmed, a tool that finds rare sperm could widen fertility treatment choices. More on Infectious disease →
- 12
Vanda eyes GLP-1 nausea approval for Nereus after phase 3 win
Source: Fierce Pharma
Vanda Pharmaceuticals is pursuing an indication for nausea linked to GLP-1 drugs for its medicine Nereus after a phase 3 trial win, Fierce Pharma reports.
Why it mattersNausea is a known side effect of GLP-1 weight-loss and diabetes drugs; Vanda wants Nereus approved to treat it after a positive late-stage trial. More on Approvals & regulatory →
- 13
Teva plans 61 job cuts as it moves to close a New Jersey plant
Source: Fierce Pharma
Teva has signalled 61 job cuts as it plans to close what it calls an underutilized plant in New Jersey, Fierce Pharma reports.
Why it mattersThe closure affects 61 workers and shows drugmakers trimming plants they consider underused.
- 14
Investigational HDAC inhibitor plus immunotherapy extends progression-free survival in unresectable melanoma
Source: MedPage Today
MedPage Today reports: (MedPage Today) -- Progression-free survival (PFS) in unresectable melanoma improved significantly with the addition of an investigational histone deacetylase (HDAC) inhibitor to immunotherapy, a randomized trial showed. Median PFS increased from...
Why it mattersA randomized trial reported at ESMO found that adding an investigational HDAC inhibitor to immunotherapy significantly improved progression-free survival in unresectable melanoma, pointing to a possible new combination for this hard-to-treat cancer. More on Oncology →
- 15
Missouri attorney general warns Lilly over 340B drug-discount data demands
Source: STAT (STAT+, paywall)
STAT reports (paywall) that Missouri's attorney general told Eli Lilly to stop forcing hospitals to hand over claims data before they can get discounted medicines under 340B, a US programme that gives clinics serving low-income patients cheaper drugs. STAT calls it a sign more states are pushing back against drugmakers.
Why it mattersThe 340B discounts help US hospitals and clinics that treat many low-income patients stretch their budgets, so fights over access to them can affect what care those sites can afford to offer.
- 16
Artiva shuts down after two deaths in autoimmune cell therapy trial
Source: STAT (STAT+, paywall)
STAT reports (paywall) that biotech company Artiva is shutting down after two deaths in its trial of a cell therapy for autoimmune disease. STAT says the deaths are a setback to drugmakers' push to use cancer-style cell therapies against autoimmune conditions.
Why it mattersCell therapies are being tested for conditions like lupus, and trial safety problems like these shape how fast, and whether, such treatments reach patients. More on Drug & device safety →
- 17
Piramal Pharma swings to Q2 profit as revenue jumps 28% and raises outlook
Source: CNBC TV18
India's Piramal Pharma reported a net profit of ₹5.58 crore for July-September versus a ₹99.2 crore loss a year earlier, as revenue rose 28% to ₹2,617 crore, led by its contract drug manufacturing (CDMO) business. It now expects 19% to 20% revenue growth for the financial year. (Company-reported.)
Why it mattersGrowth at Indian contract manufacturers signals more global drug production, and jobs, moving to India. Not investment advice. More on Pharma industry →
- 18
SkinBench test finds six AI models 'saw' skin problems that were not there
Source: Cosmetics Business
SkinBench, a benchmark for AI skin analysis, found that six general-purpose AI models misread skin and flagged problems that were not present. Cosmetics Business says it shows what beauty brands should test before trusting any vendor's results.
Why it mattersMany beauty apps and stores use AI 'skin scans' to recommend products; false findings could push people to buy products they don't need. More on Cosmetics & skincare →
- 19
Bactolife brings gut-binding proteins to US supplement market
Source: NutraIngredients
Danish company Bactolife is introducing precision-fermented 'Helm Binding Proteins' to the US gut health market, aiming to neutralise harmful substances in the gut rather than change the gut microbiome directly. The headline notes the company is seeking human data. (Company-described.)
Why it mattersGut-health supplements are a big consumer spend; until human study results are published, shoppers should treat new ingredients' benefits as unproven. More on Nutraceuticals & supplements →
- 20
India's Supreme Court slams drug regulator over expired Covid-era antifungal approvals
Source: Hindustan Times
India's Supreme Court criticised the government and the Drug Controller General of India for failing for five years to act against companies allegedly still making and selling liposomal amphotericin B, an antifungal used for 'black fungus' (mucormycosis), under emergency approvals granted in the 2021 Covid wave. The bench reserved its order and said any directions would apply to every company that got such emergency licences.
Why it mattersMedicines sold on expired emergency permissions may not have gone through normal trials and checks, so the court's ruling could affect the quality and supply of a life-saving antifungal in India. More on Approvals & regulatory →
- 21
FDA flags B. Braun dialysis bloodline sets over leak and blood-loss risk
Source: FDA MedWatch
The FDA issued an early alert that B. Braun is removing Streamline bloodline sets used with its Dialog+ dialysis machines because the dialyzer connector may not attach properly, which can cause leaks and potential blood loss.
Why it mattersPeople on dialysis depend on these tubing sets several times a week; dialysis centres using this equipment need to check stock, and patients can ask their care team whether their machine is affected. More on Approvals & regulatory →
Market news · Not investment advice
More recent digests
- Wednesday, November 18, 2026White House pulls its FDA nominee, the US loses measles elimination status, and FDA offers to share its approval reviews with other regulators
- Tuesday, November 17, 2026US flu deaths in children rise, a Cochrane review backs daily iron for anaemia, and the FDA approves giredestrant for selected breast cancers
- Monday, November 16, 2026Teen tirzepatide trial cuts BMI, US flu season starts early, and the FDA rejects Summit's lung cancer drug
- Sunday, November 15, 2026WHO issues first type 1 diabetes guidance for adults and children; JAMA reports a possible CTE blood biomarker; MP flags mercury creams
- Saturday, November 14, 2026FDA approves a weekly self-injected myasthenia gravis drug; US measles deaths rise; India enforces lower cancer-drug prices
- Friday, November 13, 2026WHO reports persistent TB burden; JAMA publishes new oncology and neonatal sepsis trials; MHRA flags a packaging defect
- Thursday, November 12, 2026WHO reports continuing Ebola emergency and African regulatory advances; FDA approves first FXIa inhibitor for secondary stroke prevention
Free daily email
The day's approvals, safety signals and trials, in five minutes.
Join the list with just your email. You can also follow the RSS feed.
